Nkarta, Inc. (NASDAQ:NKTX – Get Rating) has received an average rating of "Moderate Buy" from the nine analysts that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $28.57.

Several brokerages have issued reports on NKTX. Canaccord Genuity Group began coverage on shares of Nkarta in a report on Monday, October 10th. They issued a "buy" rating and a $25.00 price target on the stock. Oppenheimer lowered shares of Nkarta from an "outperform" rating to a "market perform" rating in a report on Thursday, December 22nd. Canaccord Genuity Group began coverage on shares of Nkarta in a report on Monday, October 10th. They issued a "buy" rating and a $25.00 price target on the stock. Mizuho lowered their price target on shares of Nkarta from $81.00 to $26.00 and set a "buy" rating on the stock in a report on Wednesday, November 16th. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Nkarta in a report on Wednesday, September 21st.

Nkarta Trading Down 0.2 %

Shares of NKTX stock opened at $5.57 on Tuesday. Nkarta has a 1 year low of $5.06 and a 1 year high of $20.35. The firm's fifty day simple moving average is $7.53 and its 200 day simple moving average is $11.66. The firm has a market capitalization of $271.89 million, a P/E ratio of -2.09 and a beta of 0.17.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in NKTX. Federated Hermes Inc. lifted its position in Nkarta by 735.3% during the 1st quarter. Federated Hermes Inc. now owns 4,711 shares of the company's stock worth $54,000 after buying an additional 4,147 shares in the last quarter. Wasatch Advisors Inc. lifted its position in Nkarta by 33.4% during the 1st quarter. Wasatch Advisors Inc. now owns 842,302 shares of the company's stock worth $9,585,000 after buying an additional 210,700 shares in the last quarter. Renaissance Technologies LLC lifted its position in Nkarta by 69.7% during the 1st quarter. Renaissance Technologies LLC now owns 234,000 shares of the company's stock worth $2,663,000 after buying an additional 96,100 shares in the last quarter. State Street Corp lifted its position in Nkarta by 1.0% during the 1st quarter. State Street Corp now owns 276,318 shares of the company's stock worth $3,144,000 after buying an additional 2,806 shares in the last quarter. Finally, Wellington Management Group LLP lifted its position in Nkarta by 5.9% during the 1st quarter. Wellington Management Group LLP now owns 27,879 shares of the company's stock worth $317,000 after buying an additional 1,554 shares in the last quarter. Institutional investors and hedge funds own 87.22% of the company's stock.

About Nkarta

(Get Rating)

Nkarta, Inc, a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells.

Recommended Stories

• Get a free copy of the StockNews.com research report on Nkarta (NKTX)
• Is Walgreens Boots Alliance Earnings Miss Good For Investors?
• Pinterest is the Social Commerce Platform to Watch in 2023
• Why Warner Bros Discovery Is the S&P's Hottest Stock
• 4 High-Yield Dividend Kings For 2023
• Will 2023 be a Good Year for Goodyear Tire Stock?

Receive News & Ratings for Nkarta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nkarta and related companies with MarketBeat.com's FREE daily email newsletter.